The CD4+ Th1 killer lymphocytes, which may recognise tumour antigens differently from CD8+ cytotoxic T lymphocytes or NK cells, may be a promising candidate for the effector cells of cancer immunotherapy that targets the heterogenous clinical tumours. This evidence concerns the gene CD8A and neoplasm.